Investors in Immersion have enjoyed the magic touch of late with shares of the touch-technology provider up over 45% in the past 3 months. Immersion CEO Victor Viegas said the hot streak in so-called 'haptics' is just getting started. 'Technology adoption is accelerating and as we move into this digital world we lose our sense of touch. Immersion is focused on allowing you to reach in and feel that digital world,' said Viegas. 'And as a result we’ve had a lot of accelerating business interests, new agreements struck that generate significant revenue from licensing our IP, our technology and solutions, so it’s a good time for Immersion.' Immersion’s technologies are now in 3 billion devices worldwide including smartphones, tablets, gaming consoles, smartwatches, cars and medical equipment. Mobile phone manufacturers that have adopted Immersion’s technology include Samsung, LG, Xiaomi, Huawei, Motorola, Meizu and HTC, which settled a long-running patent infringement suit Immersion for undisclosed sum in March. As for the future, Viegas said wearables will be a massive market for haptics going forward. 'The wearable market for us is going to be very big, it’s how we are going to operate in augmented reality, virtual reality and a number of new areas in the internet of things.'
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.